| Type 2 Diabetes Mellitus |
1 |
1 |
| Cerebrovascular Accident |
0 |
0.96 |
| Dementia |
0 |
0.99 |
| Cardiovascular Risk Management |
0 |
0.33 |
| Coronary Artery Disease (CAD) |
0 |
0.28 |
| Heart |
0 |
0.23 |
| Thromboembolism |
0 |
0.2 |
| Heart Failure (HF) |
0 |
0.18 |
| Blood |
0 |
0.08 |
| Blood Vessel |
0 |
0.08 |
| Cerebrovascular Accident History |
0 |
0.08 |
| Adherence |
0 |
0.07 |
| Bladder Cancer |
0 |
0.06 |
| Adverse Effects |
0 |
0.04 |
| Apolipoproteins |
0 |
0.04 |
| Bladder |
0 |
0.04 |
| Brain |
0 |
0.04 |
| Cancer |
0 |
0.04 |
| Clinical Guidelines |
0 |
0.04 |
| Diabetes Mellitus |
0 |
0.98 |
| Fractures |
0 |
0.04 |
| Geriatrics |
0 |
0.04 |
| Grant |
0 |
0.04 |
| Ischemic Stroke |
0 |
0.04 |
| Lipids Management |
0 |
0.04 |
| Patient Safety |
0 |
0.04 |
| Recurrent Stroke |
0 |
0.04 |
| SGLT2 Inhibitor |
0 |
0.04 |
| Weight Gain |
0 |
0.04 |
| Weight Management |
0 |
0.04 |